MAOB and Parkinson disease: Conventional pharmacological PD treatment focuses on sustaining dopamine’s effects in the dopaminergic nerves’ depleted striatum by drugs that either (a) cross the BBB and metabolise to dopamine (levodopa), (b) bind to and activate dopamine receptors (dopamine agonists), (b) attenuate the breakdown of endogenous dopamine (monoamine oxidase B and catechol-O-methyl transferase inhibitors), and (d) attempt to correct the imbalance between dopamine and acetylcholine activity in the brain (anticholinergics) [318,319,320,321,322,323,324].